What changed: Relapsed or refractory chronic lymphocytic leukaemia
Every dated change on the records linked to Relapsed or refractory chronic lymphocytic leukaemia, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval4Regulatory1Trial result4Milestone6This record1
September 2026 · 1
2025 · 1
2024 · 3
- 2024ApprovalLisocabtagene maraleucelLisocabtagene maraleucel approved in US
Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)
- 2024Trial resultBRUIN CLL-321BRUIN CLL-321 reported
PFS 11.
- 2024MilestoneBRUIN CLL-321BRUIN CLL-321 reads out; lisocabtagene maraleucel approved for double-refractory CLL
A milestone in how this cancer is treated.
2023 · 2
2022 · 2
2018 · 1
2016 · 1
February 2014 · 1
2014 · 4
- 2014ApprovalIbrutinibIbrutinib approved in US
Relapsed CLL (RESONATE); del(17p) CLL
- 2014ApprovalIdelalisibIdelalisib approved in US
Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)
- 2014Trial resultRESONATERESONATE reported
PFS HR 0.
- 2014MilestoneRESONATERESONATE: ibrutinib beats ofatumumab in relapsed CLL; idelalisib approved
A milestone in how this cancer is treated.